Obesity is known as a carcinogenic factor for colorectal cancer. Interestingly, obesity is associated with increased VEGF levels. Therefore, we aimed to investigate whether obesity affects survival in metastatic colorectal cancer (mCRC) patients who treated with bevacizumab combined chemotherapies.
Five hundred and sixty three patients with mCRC who received first-line chemotherapy combination with bevacizumab were studied retrospectively. Patients were grouped as obese (BMI levels > 30) and non-obese (BMI levels
The median age of all the patients was 59 years. Non-obese group had longer PFS than obese group (P = 0.030). 2-year survival rate of non-obese group was also significantly higher (P = 0.036). In the univariate cox regression analysis ECOG ≤1, male gender, and non-obesity were the positive factors for PFS (HRs: 0.46, 0.81, and 0.75, respectively). In the multivariate analysis ECOG performance status was found as the most powerful prognostic factor for PFS (HR: 0.47, P 1
Efficacy of bevacizumab may be lower in obese patients. Prospectively designed studies for obese patients should be done to recommend the efficacy of bevacuzimab in mCRC.
Clinical trial identification
Legal entity responsible for the study
Turkish Oncology Group (TOG)
All authors have declared no conflicts of interest.